Aurinia Adds Two Assets To Expand Its Immunology Pipeline


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


  • Aurinia Pharmaceuticals Inc (NASDAQ:AUPHhas added two assets to expand its rare autoimmune and kidney-related disease pipeline.
  • The first program, AUR200, was acquired from privately-held Thunderbolt Pharma Inc
  • AUR200 is a recombinant Fc fusion protein designed to block B-cell Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL). 
  • BAFF and APRIL promote B cell survival and play a prominent role in the pathogenesis of certain autoimmune and nephrology conditions.
  • Aurinia paid $750,000 upfront. Additionally, Thunderbolt will receive low single-digit sales-based royalties. 
  • AUR200 is in preclinical development, with IND submission expected by the end of 2022.
  • The second program, AUR300, was added via a licensing and research agreement with Riptide Bioscience Inc.
  • AUR300 is a novel peptide therapeutic that modulates M2 macrophages (a type of white blood cells) via the macrophage mannose receptor CD206. 
  • Aurinia paid Riptide an upfront fee of $6 million.
  • Clinical development for AUR300 will commence in 1H of 2023.
  • Price Action: AUPH shares closed 4.68% lower at $14.46 on Monday.

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechM&ANewsHealth CareAsset SalesSmall CapGeneralautoimmune diseasesBriefsPreclinical Phase